p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer

British Journal of Cancer

Volumn 80, Issue 12, 1999, Pages 1987-1994

  Schneider, J ^a   Presek, P ^b   Braun, A ^b   Bauer, P ^c   Konietzko, N ^c   Wiesner, B ^d   Woitowitz, H J ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Klin fur Lungenkrankheiten und T   (Germany)

Author keywords

Anti p53 antibodies; EGF R; Lung cancer; Occupational; p53 protein; Serum

Indexed keywords

ANTIBODY; ASBESTOS; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; TUMOR MARKER; VINYL CHLORIDE;

ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; ASBESTOSIS; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; IONIZING RADIATION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG METASTASIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OCCUPATIONAL CANCER; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION EXPOSURE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; AUTOANTIBODIES; CARCINOMA, LARGE CELL; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PLEURAL EFFUSION; PLEURAL NEOPLASMS; PULMONARY FIBROSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032778346     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690632     Document Type: Article

References (49)

1. Angelopoulou K, Diamandis KE, Sutherland DJ, Kellm JA and Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487
2. Ambs KE, Takahashi A, Hering F, Costa S and Huber PR (1989) Epidermal growth factor receptor in adenocarcinoma of the kidney. Urol Res 17; 251-254
3. Barker S and Vinson GP (1990) Epidermal growth factor in breast cancer. Int J Biochem 22; 939-945
4. Birrer MJ and Brown PH (1992) Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res 52: 2658s-2664s
5. Brambilla E, Gazzeri S, Moro D, Caron de Fromental C, Gouyer V, Jacrot M and Brambilla C (1993) Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143: 199-210
6. Brandt-Rauf PW (1995) The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutal Res 333: 203-208
7. Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H and Ford J (1992) Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 50: 881-885
8. Burkhart C (1994) Das Tumorsuppressorprotein p53. Dtsch Arzteblatt 91: 898-904
9. Butz M (1996) Beruflich verursachte Krebserkrankungen. Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, St. Augustin, Germany
10. Choi JH, Oh JY, Ryu SK, Kim SJ, Lee NY, Kim KS, Yi SY, Shim KS and Han WS (1997) Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 79; 1879-1893
11. De Vuyst P (1997) Guidelines for attribution of lung cancer to asbestos. In: Proceedings of an International Expert Meeting on Asbestos, Asbestosis and Cancer, People and Work, Research Reports 14: 92-96, Finnish Institute of Occupational Health; Helsinki, Finland
12. Eigenwillig GG (1997) Berufliche Strahlenexposition durch Radon und dessen Folgeprodukte, Konsequenzen für die Anerkennung als Berufskrankheit. Dtsch Ärzteblatt 94: 1057-1062
13. Fontanini G, Fiore L, Bigini D, Vignati S, Calvo S, Mussi A, Lucci M, Angeletti CA and Merlo Basolo F (1994) Levels of p53 antigen in serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvment. Int J Oncol 5: 553-558
14. Hacder M, Rotsch M, Bepler G, Henning C, Havemann K, Heimann B and Moelling K (1988) Epidermal growth factor receptor expression in human lung cancer cell lines, Cancer Res 48: 1132-1136
15. Hanaoka T, Yamano Y, Katsuno N, Kagawa J and Ishizu S (1997) Elevated serum levels of pantropic p53 in chronium workers. Scand J Work Environ Health 23: 37-40
16. Harris CC and Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. New Engl J Med 329; 1318-1327
17. Horio Y, Suzuki H, Ueda R, Koshikaca T, Sigura T, Ariyoshi Y, Shimokata K and Takahashi T (1994) Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene 9: 1231-1235
18. Husgafvel-Pursiainen K, Kannio A, Oksa P, Suitiala T, Koskinen R., Hemminiki K, Smith S, Rosenstock-Leibu R and Brandt-Rauf P (1997) Mutations, tissue accumutations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen 30: 224-230
19. Kaye FJ, Kim YW and Otterson GA (1995) Molecular biology of lung cancer. In: Molecular Genetics of Cancer, Cowell JK (ed.), pp. 179-204. BIOS Scientific: Oxford
20. Lahdeaho ML, Lehtinen T, Aine R, Hakala T and Lehtinen M (1994) Antibody response in adenovirus Elb-derived synthetic peptides and serum levels of p53 in patients with gastrointestinal and other malignant lymphomas. J Med Virol 43: 393-396
21. Levesque MA, D'Casta M and Diamandis EP (1996) p53 protein is absent from serum of patients with lung cancer. Br J Cancer 74: 1434-1440
22. Lubin R, Zaleman G, Bouchet L, Tredaniel J, Lagros Y, Cazals D, Hirsch A and Soussi T (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med 1: 701-702
23. Luo JC, Zehab R, Antilla S, Ridanpää M, Husgafvel-Pursiainen K, Vaino H, Carney W, DeVivo J. Milling C and Brandt-Rauf PW (1994) Detection of serum p53 protein in lung cancer patients. J Occup Med 36: 155-160
24. Micelli G, Donaded A and Quaranta M (1992) The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. Cell Biophys 21: 25-31
25. Minna JD (1993) The molecular biology of lung cancer pathogenesis. Chest 103: 449-456
26. Mudena B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M and Leinster SJ (1994) The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69: 1115-1119
27. Nuorva U, Makitaro R, Huhti E, Kamel D, Vähäkangas K, Bloigu R, Soini Y and Paakko P (1994) p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J Respir Crit Care Med 150: 528-533
28. Parker JE (1997) Radiological criteria: the use of chest imaging techniques in asbestos-related diseases. In: Proceedings of an International Expert Meeting on Asbestos. Asbestosis and Cancer, People and Work, Research Reports 14: 28-40, Finnish Institute of Occupational Health; Helsinki, Finland
29. Partanen R, Hemminki K, Brandt-Rauf PW, Jin CG and Koskinen H (1994a) Serum levels of growth factor receptors, EGFR and Neu in asbestosis patients: A follow-up study. Int J Oncol 4: 1025-1028
30. Partanen R, Hemminki K, Koskinen H, Luo JC, Carney WP and Brandt-Rauf PW (1994b) The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 36: 1324-1328
31. Pavelic K, Banjac Z, Pavelic J and Spaventi S (1993) Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 14: 1133-1137
32. Preudhomme C, Lubin R, Lepelley P, Vanzumbeke M and Fenaux P (1994) Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndrom and acute myeloid leukemia. Leukemia 8: 1589-1591
33. Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Vinolas N, Rosell R, Tora M, Real FX, Posner JB and Dalmau J (1997) Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 89: 381-385
34. Rusch V, Baselga J, Cordon Cardo J, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J and Dmitrovsky E (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small-cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385
35. Schlichtholz B, Tredaniel J, Lubin R, Zaleman G, Hirsch A and Soussi T (1994) Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein, Br J Cancer 69: 809-816
36. Segawa Y, Tagigawa N, Mandai K, Maeda Y, Takata I, Fujimoto N and Jnno K (1997) Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation, Lung Cancer 16: 229-238
37. Sorscher SM, Russak V, Graziano V, Cagle M, Feramisco JR and Green MR (1995) Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small-cell lung cancer. Mod Pathol 8: 450-455
38. Sozzi G, Miozzo M, Tagliabue E, Calderone C, Lombardi L, Pilotti S, Pastorino U, Pierotti MA and DellaPorta G (1991) Catogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 51: 400-404
39. Sugimura H, Weston A, Caporaso N, Shields PG, Bowman ED, Metcalf RA and Marris CC (1991) Biochemical and molecular epidemiology of cancer. Biomed Environ Sci 4: 73-92
40. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G and Anderson M (1994) p53 mutations hotspot in radon-associated lung cancer. Lancet 343: 86-87
41. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Price CC, Tamburro CC and Harris CC (1995) Anti p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87: 1400-1407
42. Trumper L, Jung W, Dahl G, Diehl V, Gause A and Pfrundschuh M (1994) Interleukin-7, interleukin-8, soluble TNF receptor and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 5: 93-96
43. Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP and Harris CC (1992) Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339: 576-580
44. van Zandwijk N, Mooi WJ and Rodenhuis S (1995) Prognostic factors in NSLCL. Recent experiences. Lung Cancer 12: 27-33
45. Weissfeld JL, Larsen RD, Niman HL and Kuller LH (1994) Evaluation of oncogene-related proteins in serum, Cancer Epidemiol Biomarkers Prev 3: 57-62
46. Wild CP, Ridanpää M, Antilla S, Lubin R, Soussi T, Husgavtel-Pursianen K and Vainio H (1995) p53 antibodies in the sera of lung cancer patients: comparison with p53 mutations in the tumor tissue. Int J Cancer 64: 176-181
47. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174
48. Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF and Carbone DP (1993) Antibodies against autologous tumour cell proteins in patients with small-cell lung cancer: associated with improved survival. J Natl Cancer Inst 85: 2018
49. Wynford-Thomas D (1991) Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. J Pathol 165: 187-201